Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-09-16 16:25:39
Reporting Period:
Filing Date:
Accepted Time:
2016-09-16 16:25:39
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1267602 Alimera Sciences Inc ALIM Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1374256 Jr S Richard Eiswirth 6120 Windward Parkway, Suite 290
Alpharetta GA 30005
President And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-15 51,471 $1.33 86,445 No 4 M Direct
Common Stock Disposition 2016-09-15 51,471 $1.51 34,974 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2016-09-15 51,471 $0.00 51,471 $1.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-10-12 No 4 M Direct
  1. This sale occurred in accordance with the Reporting Person's 10b5-1 plan adopted on August 12, 2015.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. Became exercisable with respect to 1/4 of the shares of stock which are subject to this option on 11/22/07 (the "Initial Vesting Date") and with respect to the remainder of the shares in equal increments quarterly over three years beginning on the date three (3) months from the Initial Vesting Date.